Table 3.
Change in PROMIS-29 subscale scores (all participants; estimated marginal means).
| Ashwagandha (n = 60) |
Placebo (n = 60) |
p-Value
b
|
Percentage change: Week 0 to week 12 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 0 | Weeks 1–4 (mean) | Weeks 5–8 (mean) | Weeks 9–12 (mean) | p-Value a | Week 0 | Weeks 1–4 (mean) | Weeks 5–8 (mean) | Weeks 9–12 (mean) | p-Value a | Ashwagandha | Placebo | ||
| PROMIS-29 (Physical Score) | |||||||||||||
| Mean | 42.78 | 44.71 | 45.60 | 47.66 | <0.001 | 43.51 | 44.28 | 45.30 | 47.02 | <0.001 | 0.642 | 11.41 | 8.07 |
| SE | 0.80 | 0.83 | 0.76 | 0.76 | 0.88 | 0.88 | 0.87 | 0.81 | |||||
| PROMIS-29 (Mental Score) | |||||||||||||
| Mean | 40.84 | 36.15 | 33.10 | 30.10 | <0.001 | 41.22 | 36.90 | 34.02 | 31.49 | <0.001 | 0.626 | −26.30 | −23.61 |
| SE | 0.71 | 0.87 | 0.87 | 0.90 | 0.72 | 0.71 | 0.74 | 0.75 | |||||
| PROMIS-29 (Sexual Interest) | |||||||||||||
| Mean | 47.55 | 45.92 | 45.59 | 46.03 | 0.091 | 45.88 | 44.58 | 44.91 | 45.50 | 0.656 | 0.747 | −3.20 | −0.83 |
| SE | 0.88 | 0.61 | 0.80 | 0.86 | 0.84 | 0.70 | 0.78 | 0.82 | |||||
Results (estimated means) are generated from generalized mixed-effects models adjusted for age and BMI.
a
p-Values are generated from repeated measures generalized mixed-effects models adjusted for age and BMI (time effects baseline, and the means of weeks 1–4, 5–8, and 9–12).
b
p-Values are generated from repeated measures generalized mixed-effects models adjusted for age and BMI (time × group interaction).